Our core competency lies in the strategic orchestration of commercial activities that are pivotal for early-stage drug development and successful market penetration, both in the U.S. and beyond. Our methodology is distinguished by early engagement in the clinical development process.
This proactive approach enables the assimilation of critical insights from payers, providers, and patients into the target medicine profile. The result is a meticulously crafted evidence generation plan and an all-encompassing strategy that ensures the asset’s successful commercialization.
At MIRADOR Global, we do not merely consult; we integrate. Our team of experts, armed with real-world experience in global commercialization, market access, reimbursement, and pricing strategies, becomes an extension of your existing teams. We supplement your internal capabilities with our specialized knowledge, thereby elevating your commercial launch strategy effectiveness and impact.
Chuck Peipher, Managing Director, specializes in helping biopharmaceutical companies develop innovative pricing and market access strategies. He provides brand management counsel and contributes to a wide array of strategic growth initiatives. Chuck helps our clients achieve success in early launch planning and commercial preparedness, clinical pipeline development, and global business consulting.
Chuck has more than 25 years of corporate and consulting experience, including helping to build three life-science based businesses. Chuck’s foundation of experience was gained through his time with AstraZeneca with a variety of specialty care experiences – from the company’s global market-leading mental health drug Seroquel to its first orphan drug (Caprelsa for thyroid cancer). He had senior roles in brand management, healthcare provider marketing, and pricing and market access while also supporting major business development efforts. Chuck’s last position with AstraZeneca was leading the Global Pricing and Market Access team for specialty care support oncology, respiratory, infection, and CNS therapeutic areas.
As part of MIRADOR Global, Fusun Sevgen partners with clients on developing marketing, pricing, and market access strategies, supporting drug commercialization, new launches, and other strategic initiatives. Fusun is a strategic leader with a track record for developing marketing and access strategies across the product lifecycle, in particular the ability to transform scientific evidence and customer insights into strategies and resources that deliver value to physicians, patients, and payers. She is passionate about developing and supporting individuals and teams with whom she works to achieve growth and success.
Fusun has more than 25 years of pharma industry experience spanning marketing, business management, and sales with deep understanding of global markets, including the U.S., Europe, and Asia. During her career at AstraZeneca, Fusun has had Product Manager, Marketing Manager, and Brand Director roles responsible for developing and implementing launch plans for a range of brands in Europe, Asia and the U.S. She was also Global Pricing and Market Access Director for several brands, responsible for developing payer strategies and resources.
Chelsea Cooper provides Medical Affairs insight into the development of commercial brand strategies and activities; researches and interprets local, regional, and global competitive landscapes; supports the implementation and delivery of a variety of external stakeholder engagements such as advisory boards, roundtable meetings, market research, regional meetings, and Congress activities; and supports the development of medical and sales training materials in preparation for launch.
Chelsea has 15 years of experience in pharma and pharmaceutical consulting. This includes roles in Global Medical Affairs, Promotional Regulatory Affairs, Medical Communications, Speaker Training, and Sales Training. Her core expertise is providing both strategic and tactical Medical Affairs support to biopharma companies with assets that are approaching and/or active in clinical development, including development of competitive TPP/C documents, competitive landscape assessment, portfolio and/or asset assessment and prioritization, payer evidence gap analysis, HEOR project management, Medical Affairs launch planning, and content development for external stakeholder engagement activities.
Rebecca Shindel manages projects ranging from data strategy to claims data analysis to market research, where each project is customized to the client’s needs. Looking at strategy holistically, Rebecca uses several different methodologies to help clients with market sizing, forecasting, pipeline and landscape analysis, target product profile development, and custom market research to refine launch strategies. She also has expertise in creating, customizing, and adapting content to drive sales and marketing efforts – always looking for ways that content can create connections that help drive financial results.
Rebecca has more than 15 years of marketing, sales, operations, and communications roles in both pharmaceuticals and banking. This includes experience in project management, marketing, market research, training, and forecasting and analytics. She has worked with diverse market leaders including AstraZeneca, Alfred I. DuPont Hospital for Children, and Capital One Bank.
Thomas Ross, Executive Director of Commercial Strategy is a veteran of the pharmaceutical industry with over 27 years on the manufacturer side. With roles in strategic planning, market research, secondary data analytics, brand forecasting, competitive intelligence, and performance assessment across all customer segments and various therapeutic areas Tom brings a broad perspective to all his engagements. Tom has worked with brands in all phases of the product life-cycle including pre-launch, multiple brand and indication launches, growth phase and Loss of Exclusivity. A former AstraZeneca executive, Tom lead the US CVMD Insights & Analytics team and was a member of the US Cardiovascular Metabolic Disease leadership team.
Lizzie is an innovative and accomplished global pricing and market access expert with a deep understanding of payer needs and experience in the design and development of robust pricing and market access strategies to drive differentiated product value. With excellent communication and leadership skills she engages collaboratively across multiple stakeholders to identify opportunities and develop clear insights, strategies and recommendations.
Lizzie has 20+ years pharmaceutical industry experience at AstraZeneca, Allergan (now AbbVie) and GSK in both global and marketing company roles. As a global pricing and market access director she has led the cross functional development of payer evidence, value propositions and pricing and market access strategy for assets in phase 2/3 development predominantly in nephrology/kidney disease and cardiovascular disease and provided support through multiple investment decisions. She has also developed and led a comprehensive payer advisory board program across multiple payer archetypes and markets including US, EU, AsiaPac and LatAm and facilitated the integration of key insights across both clinical and commercial teams. Furthermore, Lizzie has also worked on discreet projects for products in immunology, rare and orphan diseases and NASH.
Karin Turturro-Iuzzini, Vice President of Global Commercial Strategy, will utilize her decades of experience to support our clients in early phase commercialization strategy, forecasting, asset valuation support, payer reimbursement, risk assessment and mitigation, and portfolio/product opportunity assessment and prioritization – all leading up to launch planning.
Karin brings more than 20 years of biopharmaceutical experience to COEUS. She has had great success in building and leading award-winning sales teams, creating dynamic learning and development curricula, and designing and executing marketing strategies, including new product planning. Karin’s collaborative and communicative leadership has driven the success of her cross-functional teams in pre-launch, launch, and post-launch settings. Karin has enjoyed learning and working within many therapeutic areas, including oncology, hematology, rare disease, CNS, respiratory, and cardiovascular – all while keeping a patient-centric vision and approach.